PAQR5 and hepatocellular carcinoma: To further validate the effects of W-13 and dasatinib on the PAQR5 expression in HCC, we used the W-13 and dasatinib to intervene HCC cells, and the western blot analysis substantiated that both W-13 and dasatinib effectively downregulated the PAQR5 expression in HCC cells (Fig S6C, S6D).